In last trading session, Prothena Corporation plc (NASDAQ:PRTA) saw 0.73 million shares changing hands with its beta currently measuring -0.01. Company’s recent per share price level of $15.56 trading at $0.31 or 2.03% at ring of the bell on the day assigns it a market valuation of $837.26M. That closing price of PRTA’s stock is at a discount of -99.42% from its 52-week high price of $31.03 and is indicating a premium of 24.81% from its 52-week low price of $11.70.

For Prothena Corporation plc (PRTA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 15 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.1 in the current quarter.

Prothena Corporation plc (NASDAQ:PRTA) trade information

Upright in the green during last session for gaining 2.03%, in the last five days PRTA remained trading in the green while hitting it’s week-highest on Friday, 02/21/25 when the stock touched $15.56 price level, adding 6.66% to its value on the day. Prothena Corporation plc’s shares saw a change of 12.35% in year-to-date performance and have moved 12.02% in past 5-day. Prothena Corporation plc (NASDAQ:PRTA) showed a performance of 7.83% in past 30-days.

Wall Street analysts have assigned a consensus price target of 56 to the stock, which implies a rise of 72.21% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 98. It follows that stock’s current price would drop -54.24% in reaching the projected high whereas dropping to the targeted low would mean a loss of -54.24% for stock’s current value.

Prothena Corporation plc (PRTA) estimates and forecasts

This year revenue growth is estimated to fall -59.68% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.45M for the same. And 5 analysts are in estimates of company making revenue of 21.47M in the next quarter. Company posted 50k and 132.01M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -3.15% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -58.64% while estimates for its earnings growth in next 5 years are of -9.37%.

Prothena Corporation plc (NASDAQ:PRTA)’s Major holders

ECOR1 CAPITAL, LLC is the top institutional holder at PRTA for having 11.58 million shares of worth $239.1 million. And as of 2024-06-30, it was holding 21.5453 of the company’s outstanding shares.

The second largest institutional holder is FMR LLC, which was holding about 8.07 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.016 of outstanding shares, having a total worth of $166.48 million.

On the other hand, Vanguard Specialized-Health Care Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 4.5 shares of worth $70.09 million or 8.37% of the total outstanding shares. The later fund manager was in possession of 2.32 shares on Dec 31, 2024 , making its stake of worth around $36.14 million in the company or a holder of 4.32% of company’s stock.